Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
14. Mai 2024 16:00 ET
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
[Latest] Global Bispecific Antibodies Market Size/Share Worth USD 53.8 Billion by 2033 at a 24.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
04. April 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 04, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Bispecific Antibodies Market Size, Trends and Insights By Application (Cancer...
Dyadic to Attend Industry Events in March
01. März 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
21. Februar 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
01. Februar 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02. Januar 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Present at BioProcess International
12. September 2023 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Immunohistochemistry Market worth $3.58 Billion by 2028 - Exclusive Report by The Insight Partners
29. August 2023 07:48 ET
|
The Insight Partners
Pune, India, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immunohistochemistry is a tool used microscopy-based techniques to observe cellular components such as proteins or other macromolecules in a tissue...
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
09. August 2023 16:00 ET
|
Dyadic International, Inc.
Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited...
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
26. Juli 2023 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...